Business Context and Reporting Period
This Form 8-K Current Report was filed by X4 Pharmaceuticals, Inc. on October 14, 2021. The filing discloses a corporate governance event involving the appointment of a new director to the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
The material change reported is the appointment of Francoise de Craecker as a member of the Board of Directors, effective October 14, 2021. She will serve as a Class III director until the 2023 Annual Meeting of Stockholders. Additionally, she has been appointed to the Compensation Committee, replacing Alison Lawton, who remains on the Board.
Guidance, Outlook, and Compensation Details
Ms. de Craecker will be compensated according to the Company's standard arrangements for non-employee directors. As part of her appointment, she received an initial equity award consisting of an option to purchase 12,250 shares of common stock. Key terms of this award include:
- Exercise Price: Equal to the closing price of the Company's common stock on October 14, 2021.
- Term: Ten years from the date of the award.
- Vesting Schedule: 33.3333% vests on the 12-month anniversary; the remainder vests in equal monthly installments of 2.7777% until the 36-month anniversary.
- Acceleration: 100% of the shares vest upon a change in control of the Company.
The filing does not provide specific guidance, outlook, or risk factors beyond standard disclosures regarding the director appointment.
Investor Verification Checklist
- Verify the closing stock price of X4 Pharmaceuticals on October 14, 2021, to determine the exercise price of the new director's option grant.
- Review the Company's definitive proxy statement on Schedule 14A (filed April 20, 2021) for details on standard non-employee director compensation.
- Confirm the total number of outstanding shares and the impact of the 12,250 new options on potential dilution.
- Monitor future filings for the 2023 Annual Meeting of Stockholders regarding the re-election of Class III directors.